Didier Meulien

1.6k total citations
25 papers, 606 citations indexed

About

Didier Meulien is a scholar working on Psychiatry and Mental health, Pharmacology and Epidemiology. According to data from OpenAlex, Didier Meulien has authored 25 papers receiving a total of 606 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Psychiatry and Mental health, 8 papers in Pharmacology and 7 papers in Epidemiology. Recurrent topics in Didier Meulien's work include Schizophrenia research and treatment (11 papers), Substance Abuse Treatment and Outcomes (6 papers) and Alcohol Consumption and Health Effects (6 papers). Didier Meulien is often cited by papers focused on Schizophrenia research and treatment (11 papers), Substance Abuse Treatment and Outcomes (6 papers) and Alcohol Consumption and Health Effects (6 papers). Didier Meulien collaborates with scholars based in United States, Denmark and Sweden. Didier Meulien's co-authors include Martin Brecher, Ola Svensson, Frank Miller, S. Charles Schulz, René S. Kahn, Eva Kohegyi, George T. Grossberg, Ross A. Baker, Mary Hobart and Robert D. McQuade and has published in prestigious journals such as Biological Psychiatry, Neuropsychopharmacology and Movement Disorders.

In The Last Decade

Didier Meulien

25 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Didier Meulien United States 14 309 144 136 108 95 25 606
Jochen Mutschler Germany 16 97 0.3× 96 0.7× 192 1.4× 155 1.4× 95 1.0× 57 723
Xavier Masramón Spain 15 321 1.0× 166 1.2× 65 0.5× 52 0.5× 189 2.0× 24 729
I. Gaertner Germany 12 320 1.0× 171 1.2× 49 0.4× 156 1.4× 50 0.5× 13 715
Otto‐Michael Lesch Austria 13 165 0.5× 140 1.0× 212 1.6× 226 2.1× 48 0.5× 30 710
Christopher Clyde United States 8 528 1.7× 147 1.0× 70 0.5× 73 0.7× 97 1.0× 9 873
H. Oberbauer Austria 14 457 1.5× 90 0.6× 181 1.3× 207 1.9× 287 3.0× 17 1.1k
Mario Vitali Italy 17 75 0.2× 66 0.5× 145 1.1× 139 1.3× 65 0.7× 48 675
Chamindi Seneviratne United States 19 96 0.3× 109 0.8× 275 2.0× 371 3.4× 89 0.9× 34 834
C. Stuppaeck Austria 14 343 1.1× 144 1.0× 55 0.4× 62 0.6× 33 0.3× 23 637
I Maany United States 12 132 0.4× 94 0.7× 224 1.6× 223 2.1× 51 0.5× 20 557

Countries citing papers authored by Didier Meulien

Since Specialization
Citations

This map shows the geographic impact of Didier Meulien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Didier Meulien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Didier Meulien more than expected).

Fields of papers citing papers by Didier Meulien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Didier Meulien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Didier Meulien. The network helps show where Didier Meulien may publish in the future.

Co-authorship network of co-authors of Didier Meulien

This figure shows the co-authorship network connecting the top 25 collaborators of Didier Meulien. A scholar is included among the top collaborators of Didier Meulien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Didier Meulien. Didier Meulien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Witkiewitz, Katie, Raymond F. Anton, Stephanie S. O’Malley, et al.. (2025). Reductions in World Health Organization Risk Drinking Levels as a Primary Efficacy End Point for Alcohol Clinical Trials. JAMA Psychiatry. 82(12). 1246–1246. 1 indexed citations
2.
Cutler, Andrew J., Tram Tran-Johnson, Amir H Kalali, et al.. (2025). A Failed 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of Once-Daily Extended Release Quetiapine Fumarate in Patients with Acute Schizophrenia: Lessons Learned. Psychopharmacology Bulletin. 43(4). 37–69. 1 indexed citations
3.
Wiedemann, Jonas, et al.. (2024). Randomized Phase I Trial of the α‐Synuclein Antibody Lu AF82422. Movement Disorders. 39(6). 936–944. 18 indexed citations
4.
Rascol, Olivier, et al.. (2022). A Randomized, Double‐Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease. Movement Disorders. 37(5). 1088–1093. 29 indexed citations
5.
Grossberg, George T., Eva Kohegyi, Mette Krog Josiassen, et al.. (2019). Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. American Journal of Geriatric Psychiatry. 28(4). 383–400. 95 indexed citations
6.
Falk, Daniel E., Stephanie S. O’Malley, Katie Witkiewitz, et al.. (2019). Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials. JAMA Psychiatry. 76(4). 374–374. 78 indexed citations
7.
Mueller, Sebastian, et al.. (2019). Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis. Alcohol and Alcoholism. 55(1). 63–70. 7 indexed citations
8.
Brotons, Carlos, et al.. (2018). Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care. European Addiction Research. 24(6). 293–303. 15 indexed citations
9.
Mick, Inge, John McGonigle, Mark Bolstridge, et al.. (2017). Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. Biological Psychiatry. 81(11). 941–948. 27 indexed citations
10.
Anton, Raymond F., Raye Z. Litten, Daniel E. Falk, et al.. (2011). The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders. Neuropsychopharmacology. 37(2). 402–411. 25 indexed citations
11.
Meulien, Didier, Karin Huizar, & Martin Brecher. (2010). Safety and tolerability of once‐daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double‐blind, placebo‐controlled studies. Human Psychopharmacology Clinical and Experimental. 25(2). 103–115. 20 indexed citations
12.
Newcomer, John W., Robert E. Ratner, Jan W. Eriksson, et al.. (2009). A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone. The Journal of Clinical Psychiatry. 70(4). 487–499. 49 indexed citations
13.
Möller, Hans‐Jürgen, et al.. (2008). Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. International Clinical Psychopharmacology. 23(2). 95–105. 18 indexed citations
14.
Meulien, Didier, Martin Brecher, & Karin Huizar. (2008). Once-daily extended release quetiapine fumarate (quetiapine xr): Pooled safety data from 3 placebo-controlled monotherapy studies in acute schizophrenia. European Psychiatry. 23. S132–S132. 1 indexed citations
15.
16.
Kahn, René S., et al.. (2007). Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Acute Schizophrenia. The Journal of Clinical Psychiatry. 68(6). 832–842. 83 indexed citations
17.
Peuskens, Joseph, Jitendra K. Trivedi, Martin Brecher, et al.. (2007). Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.. PubMed. 4(11). 34–50. 49 indexed citations
18.
Peuskens, J., Jitendra K. Trivedi, Martin Brecher, et al.. (2007). Randomised, placebo-controlled, relapse-prevention study with once-daily quetiapine sustained release in patients with schizophrenia. European Psychiatry. 22. S132–S132. 2 indexed citations
19.
Dubois, Bruno, Ian G. McKeith, Jean‐Marc Orgogozo, Owen Collins, & Didier Meulien. (1999). A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. International Journal of Geriatric Psychiatry. 14(11). 973–982. 41 indexed citations
20.
Bieber, Florian, et al.. (1997). 1-42-05 Clinical studies of metrifonate as a treatment for Alzheimer's disease: An overview. Journal of the Neurological Sciences. 150. S59–S60. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jochen Mutschler Breakdown of academic impact, for papers by Xavier Masramón Breakdown of academic impact, for papers by I. Gaertner Breakdown of academic impact, for papers by Otto‐Michael Lesch Breakdown of academic impact, for papers by Christopher Clyde Breakdown of academic impact, for papers by H. Oberbauer Breakdown of academic impact, for papers by Mario Vitali Breakdown of academic impact, for papers by Chamindi Seneviratne Breakdown of academic impact, for papers by C. Stuppaeck Breakdown of academic impact, for papers by I Maany
Rankless by CCL
2026